Bile Acids Therapeutics
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company developing therapeutics for the treatment of chronic fibrotic and
Founded by Dr. Mark Pruzanski in 2002, Intercept's science is based on discoveries around bile acids acting as complex signaling molecules involved in the maintenance of lipid and glucose homeostasis, while also preserving functional integrity of the liver and other organs. Intercept's core technology was developed by leading bile acid researchers at the University of Perugia in Italy.
The company is listed on the NASDAQ under the symbol ICPT
For more information on Intercept Pharmaceutical's scientific programs visit the company website at